PS-002 for the Treatment of IgA Nephropathy in Adults

The purpose of the study is to evaluate safety, tolerability, and preliminary effectiveness following administration of PS-002 in adults with primary Immunoglobulin A (IgA) nephropathy. This will be a first-in-human study and will include participants at high risk of disease progression despite receiving current standard-of-care treatment. Participants will be monitored for up to one year after receiving PS-002 and invited to take part in a long-term follow-up study (total follow-up: 5 years).

NCT Number	NCT07182227
Lead Sponsor	Purespring Therapeutics Limited
Conditions	Immunoglobulin A (IgA) Nephropathy
Enrollment	32 participants
Start Date	2026-03-30
Primary Completion	2028-09 (estimated)
Study Completion	2029-09 (estimated)
Updated on ClinicalTrials.gov	2026-06-30